Joseph Daniel Buxbaum

Joseph Daniel Buxbaum

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Joseph Daniel Buxbaum

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
E(European Alzheimer'S Disease Initiative (Eadi)
European Alzheimer'S Disease Initiative (Eadi)
JLJean-Charles Lambert
Jean-Charles Lambert
G(Genetic And Environmental Risk In Alzheimer'S Disease (Gerad)
Genetic And Environmental Risk In Alzheimer'S Disease (Gerad)
A(Alzheimer's Disease Genetic Consortium (ADGC)
Alzheimer's Disease Genetic Consortium (ADGC)
C(Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
PAPhilippe Amouyel
Philippe Amouyel

28 February 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBrian W. Kunkle
Brian W. Kunkle
T(The European Alzheimer’s Disease Initiative (Eadi)
The European Alzheimer’s Disease Initiative (Eadi)
BGBenjamin Grenier-Boley
Benjamin Grenier-Boley
RSRebecca Sims
Rebecca Sims
JBJoshua C. Bis
Joshua C. Bis
MPMargaret A. Pericak-Vance
Margaret A. Pericak-Vance

29 October 2014 in Nature
Verified
Journal Article
Open access
PDF file
SRSilvia De Rubeis
Silvia De Rubeis
XHXin He
Xin He
AGArthur P. Goldberg
Arthur P. Goldberg
CPChristopher S. Poultney
Christopher S. Poultney
KSKaitlin Samocha
Kaitlin Samocha
JBJoseph D. Buxbaum
Joseph D. Buxbaum
The genetic architecture of autism spectrum disorder involves the interplay of common and rare variants and their impact on hundreds of genes. Using exome sequencing, here we show that analysis of rare coding variation in 3,871 autism cases and 9,937 ancestry-matched or parental controls implicates 22 autosomal genes at a false discovery rate (FDR) < 0.05, plus a set of 107 autosomal genes strongly enriched for those likely to affect risk (FDR < 0.30). These 107 genes, which show unusual evolutionary constraint against mutations, incur de novo loss-of-function mutations in over 5% of autistic subjects. Many of the genes implicated encode proteins for synaptic formation, transcriptional regulation and chromatin-remodelling pathways. These include voltage-gated ion channels regulating the propagation of action potentials, pacemaking and excitability–transcription coupling, as well as histone-modifying enzymes and chromatin remodellers—most prominently those that mediate post-translational lysine methylation/demethylation modifications of histones.

25 February 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JGJakob Grove
Jakob Grove
SRStephan Ripke
Stephan Ripke
TAThomas D. Als
Thomas D. Als
MMManuel Mattheisen
Manuel Mattheisen
RWRaymond K. Walters
Raymond K. Walters
BUBupgen
Bupgen
Autism spectrum disorder (ASD) is a highly heritable and heterogeneous group of neurodevelopmental phenotypes diagnosed in more than 1% of children. Common genetic variants contribute substantially to ASD susceptibility, but to date no individual variants have been robustly associated with ASD. With a marked sample-size increase from a unique Danish population resource, we report a genome-wide association meta-analysis of 18,381 individuals with ASD and 27,969 controls that identified five genome-wide-significant loci. Leveraging GWAS results from three phenotypes with significantly overlapping genetic architectures (schizophrenia, major depression, and educational attainment), we identified seven additional loci shared with other traits at equally strict significance levels. Dissecting the polygenic architecture, we found both quantitative and qualitative polygenic heterogeneity across ASD subtypes. These results highlight biological insights, particularly relating to neuronal function and corticogenesis, and establish that GWAS performed at scale will be much more productive in the near term in ASD.

23 January 2020 in Cell
Verified
Journal Article
Closed access
FSF. Kyle Satterstrom
F. Kyle Satterstrom
JKJack A. Kosmicki
Jack A. Kosmicki
JWJiebiao Wang
Jiebiao Wang
MBMichael S. Breen
Michael S. Breen
SRSilvia De Rubeis
Silvia De Rubeis
JBJoseph D. Buxbaum
Joseph D. Buxbaum

3 April 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ANAdam C Naj
Adam C Naj
GJGyungah Jun
Gyungah Jun
GBGary W Beecham
Gary W Beecham
LWLi-San Wang
Li-San Wang
BVBadri Narayan Vardarajan
Badri Narayan Vardarajan
GSGerard D Schellenberg
Gerard D Schellenberg
Gerard Schellenberg and colleagues report a genome-wide association study of late-onset Alzheimer's disease (LOAD), as part of the Alzheimer Disease Genetics Consortium. They identify common variants in MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 associated with LOAD. The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association study of late-onset Alzheimer disease using a three-stage design consisting of a discovery stage (stage 1) and two replication stages (stages 2 and 3). Both joint analysis and meta-analysis approaches were used. We obtained genome-wide significant results at MS4A4A (rs4938933; stages 1 and 2, meta-analysis P (PM) = 1.7 × 10−9, joint analysis P (PJ) = 1.7 × 10−9; stages 1, 2 and 3, PM = 8.2 × 10−12), CD2AP (rs9349407; stages 1, 2 and 3, PM = 8.6 × 10−9), EPHA1 (rs11767557; stages 1, 2 and 3, PM = 6.0 × 10−10) and CD33 (rs3865444; stages 1, 2 and 3, PM = 1.6 × 10−9). We also replicated previous associations at CR1 (rs6701713; PM = 4.6 × 10−10, PJ = 5.2 × 10−11), CLU (rs1532278; PM = 8.3 × 10−8, PJ = 1.9 × 10−8), BIN1 (rs7561528; PM = 4.0 × 10−14, PJ = 5.2 × 10−14) and PICALM (rs561655; PM = 7.0 × 10−11, PJ = 1.0 × 10−10), but not at EXOC3L2, to late-onset Alzheimer's disease susceptibility1,2,3.